Orchard Therapeutics proposes IPO

Orchard Therapeutics Ltd. (London, U.K.) proposed to raise up to $172.5 million in an IPO on NASDAQ underwritten by J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow.

Orchard is developing autologous ex vivo lentiviral gene therapies to treat rare primary immune deficiencies and inherited metabolic disorders.